Delivery Order SPE2DB20D1100-SPE2DB25FA0G7

Award Date 1/13/25
Potential Completion Date 2/4/25
Potential Value $3.7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,027.70, is a delivery order for the supply of the prescription medication Ingrezza 80 mg capsules. The contract is a firm fixed-price, non-set-aside award with a performance period through May 1, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,027.70 firm fixed-price delivery order is for the supply of 4,568,157,128 units of the pharmaceutical product Ingrezza 80 mg capsules. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC)...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, valued at $3,714.98. The contract is for the supply of 4561707386 Ingrezza 80 mg capsules. The contract has an ultimate completion date of August 25, 2023 and is a firm fixed price, delivery order contract type. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,027.70 firm fixed-price delivery order is for the supply of 4,568,061,451 units of the 80 mg capsule of the drug Ingrezza. The contract has a performance period extending through May 19, 2025. AmerisourceBergen Drug Corp holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ingrezza 60 mg capsules. The order has a firm fixed price of $3,914.32 and an ultimate completion date of November 5, 2024. This contract is not set aside for any specific business type. AmerisourceBergen holds several Indefinite Delivery Contracts (IDCs) with the DLA and other federal agencies, valued up to $999,999,999 and $750,000,...
This federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp is for the delivery of Ingrezza 40 mg capsules. The $3,119.55 firm fixed-price delivery order has an ultimate completion date of April 10, 2023. The contract is not designated with a set-aside requirement, indicating open competition. AmerisourceBergen, a major pharmaceutical distributor, holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,119.55 firm fixed price delivery order is for the supply of INGREZZA 40 MG CAPSULE 30S, a pharmaceutical product. The contract has a completion date of February 6, 2023 and was awarded on January 13, 2023. This order is a part of Amerisourcebergen's larger $999,999,999 Indefinite Delivery Contract (IDC) with...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $3,119.55 firm-fixed-price contract is for the delivery of Ingrezza 40 mg capsules, a specialty medication, to support military healthcare programs. The contract has a completion date of June 21, 2023 and is not set aside for any specific business type. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,027.70 Firm Fixed Price Delivery Order contract is for the supply of INGREZZA 80 MG CAPSULE 30S, a pharmaceutical product. The contract has an ultimate completion date of March 6, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,676.12, is a delivery order for 4567221736 INGREZZA 40 MG CAPSULE 30S, with a performance period ending on March 4, 2025. The contract is a Firm Fixed Price arrangement, with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
  • SPE2DB20D1100
    Indefinite Delivery Contract
  • SPE2DB20D1100-SPE2DB25FA0G7
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $3,676.12 firm fixed-price delivery order is for the drug Ingrezza 40 mg capsules. The contract has an ultimate completion date of February 4, 2025. AmerisourceBergen holds a large Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999 through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation valued at $750,000 through May 2024, covering similar medical products and prescription drugs. This contract award was not designated as a set-aside contract.

Generated 4/21/25, 3:33 AM